PT  - JOURNAL ARTICLE
AU  - S. A. Baylis
AU  - J. BlÜmel
TI  - Regulatory Expectations of Validation/Qualification of Adventitious Virus Assays
DP  - 2010 Sep 01
TA  - PDA Journal of Pharmaceutical Science and Technology
PG  - 486--491
VI  - 64
IP  - 5
4099  - http://journal.pda.org/content/64/5/486.short
4100  - http://journal.pda.org/content/64/5/486.full
SO  - PDA J Pharm Sci Technol2010 Sep 01; 64
AB  - The European Union (EU) guideline concerning the virus safety evaluation of biotechnological investigational medicinal products (CPMP/BWP/398498/2005) recently came into force. In the guideline it is stated that analytical procedures supporting the qualification of cell banking systems, starting materials, as well as testing of unprocessed bulks for the presence of adventitious viruses, should be supported by appropriate qualification/validation studies. The validation protocols should prospectively set claims for assay performance, which should be verified by the validation experiments and demonstrate that a particular procedure is suitable for its intended purpose. Assay parameters for adventitious virus testing are discussed, and examples of validation of qualitative and quantitative assays for the detection of blood-borne viruses in human plasma are considered.